Novo Nordisk second best science employer in the world

Novo NordiskNovo Nordisk ranked second in the 2014 Science Careers Top Employers Survey, which is a big jump up the list from last year's ranking where Novo Nordisk came in at number 11. The key drivers of the ranking were the categories 'Treats employees with respect', 'Has loyal employees' and 'Is socially responsible'.

"We're really proud of being ranked number two this year on the prestigious list of the world's best science employers," said Mads Krogsgaard Thomsen, chief science officer and executive vice president at Novo Nordisk. "Our researchers around the world are doing a tremendous job of discussing and developing truly innovative and patient-focused products. The fact that the research community feels that Novo Nordisk is one of the very best places to work matters a great deal for a company growing at Novo Nordisk's pace."

Today Novo Nordisk employs more than 40,000 people globally - a number the company anticipates will rise to more than 60,000 over the next decade. Novo Nordisk Research and Development is a global organisation with more than 6,000 employees working at sites in Denmark, China, US and India.

Novo Nordisk has more than 90 years of experience as a science-driven company with a strong commitment to patients.

"We combine scientific, pharmaceutical and clinical expertise with high ethical standards to continue to improve the quality of life of people living with chronic diseases. As the global leader in diabetes care, millions of people worldwide rely on us to deliver treatments for their disease every day. Additionally, we continue to invest in developing innovative treatments for obesity, haemophilia and growth disorders," says Mads Krogsgaard Thomsen.

The 2014 Science Careers Top Employers Survey is based on 5,394 responses from readers of Science and from employees in the biotechnology and pharmaceutical industry, who were asked to rank the 20 best employers on a number of characteristics.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...